Mitochondria in Motion, Inc.
Saint Louis, MO · Biotech · Private
Small molecule mitofusin activators (trans-MiM111) to treat Charcot-Marie-Tooth disease 2A and other mitochondrial neurodegeneration disorders
- Grants
- $5.9M
- 8 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 3
- 0 granted · 3 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20192020202120222023
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Mitofusin Agonists To Treat Neurodegenerative Disease | $557,263 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Mitofusin agonists to prevent Charcot-Marie-Tooth disease 2A | $254,379 | |
| Federal grant | Department of Health and Human Services · Phase I · Mitofusin Agonists To Treat Neurodegenerative Disease | $224,701 | |
| Federal grant | Department of Health and Human Services · Phase I · Mitofusin Agonists To Treat Neurodegenerative Disease | $78,500 | |
| Federal grant | Department of Health and Human Services · Phase II · Mitofusin agonists to prevent Charcot-Marie-Tooth disease 2A | $1,960,976 | |
| Federal grant | Department of Health and Human Services · Phase II · Mitofusin Agonists to Treat Neurodegenerative Disease | $968,715 | |
| Federal grant | Department of Health and Human Services · Phase II · Mitofusin agonists to prevent Charcot-Marie-Tooth disease 2A | $901,762 | |
| Federal grant | Department of Health and Human Services · Phase II · Mitofusin Agonists to Treat Neurodegenerative Disease | $986,168 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2595 | Animantis LLC | — | $550K |
| 2596 | EVRYS BIO LLC | — | $548K |
| 2597 | Nascent Biotech Inc. | — | $543K |
| 2598 | Mitochondria in Motion, Inc. | — | — |
| 2599 | SKYRAN BIOLOGICS, INC. | — | — |
| 2600 | Aurora Bio, Inc. | — | — |
| 2601 | NEURODON, LLC | — | $500K |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- TRANS-4-HYDROXYCYCLOHEXYL Phenyl Amide Mitofusin Activators And Methods Of Use Thereofapplication
- N-(TRANS-4-HYDROXYCYCLOHEXYL)-6-PHENYLHEXANAMIDEDERIVATIVES And Related Usesapplication
- N-(TRANS-4-HYDROXYCYCLOHEXYL)-6-PHENYLHEXANAMIDE Derivatives And Related Usesapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.